← Back to Screener
BioVie Inc. Warrant (BIVIW)
Price$0.30
Favorite Metrics
Price vs S&P 500 (4W)-23.78%
All Metrics
Price vs S&P 500 (YTD)14.35%
10-Day Avg Trading Volume0.03M
3-Month Avg Trading Volume0.01M
52-Week High$0.52
13-Week Price Return15.38%
3-Month Return Std Dev222.28%
Year-to-Date Return16.69%
5-Day Price Return14.07%
Month-to-Date Return-3.23%
Price vs S&P 500 (13W)12.52%
52-Week Low$0.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BIVIWBioVie Inc. Warrant | — | — | — | — | $0.30 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
BioVie Inc is a clinical-stage biopharmaceutical company developing drug therapies for chronic debilitating conditions including liver disease, neurological and neuro-degenerative disorders, and certain cancers. The company is advancing NE3107 through a Phase 3 clinical trial for mild to moderate Alzheimer's disease. BIV201 is being developed to address life-threatening complications of liver cirrhosis caused by hepatitis, non-alcoholic steatohepatitis, and alcoholism.